Research Papers
This database includes peer-reviewed publications authored or funded by TB Alliance. Use the tags on the right to filter by subject, or search for a particular author or term using the search bar.
Displaying 176 papers
Next-Generation Diarylquinolines Improve Sterilizing Activity of Regimens with Pretomanid and the Novel Oxazolidinone TBI-223 in a Mouse Tuberculosis Model
3/2023 - Antimicrobial Agents and Chemotherapy
Community engagement in tuberculosis research: the EU-Patient-cEntric clinicAl tRial pLatforms (EU-PEARL) experience
3/2023 - International Journal of Infectious Diseases
Sugar and sugar-free liquid formulations of delamanid for patients with rifampicin-resistant TB
1/2023
Lifesaving, cost-saving: Innovative simplified regimens for drug-resistant tuberculosis
11/2022 - PLOS Global Public Health
Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis
9/2022 - New England Journal of Medicine
Assessment of the Carcinogenic Potential of Pretomanid in Transgenic Tg.rasH2 Mice
7/2022 - International Journal of Toxicity
Toxicity and toxicokinetic assessment of an anti-tubercular drug pretomanid in cynomolgus monkeys
4/2022 - Toxicology Reports
Ancient and recent differences in the intrinsic susceptibility of Mycobacterium tuberculosis complex to pretomanid
3/2022 - Antimicrobial Chemotherapy
Single Ascending-Dose Study To Evaluate the Safety, Tolerability, and Pharmacokinetics of Sutezolid in Healthy Adult Subjects
3/2022 - Antimicrobial Chemotherapy
Budgetary impact of using BPaL for treating extensively drug resistant tuberculosis
1/2022 - BMJ Global Health
Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant Rv0678 Mutant in a Mouse Model of Tuberculosis
12/2021 - Antimicrobial Agents and Chemotherapy
Acceptability, feasibility, and likelihood of stakeholders implementing the novel BPaL regimen to treat extensively drug-resistant tuberculosis patients
7/2021 - BMC Public Health
Pretomanid with Bedaquiline and Linezolid for Drug Resistant TB: A Comparison of Prospective Cohorts
4/2021
A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB
3/2021 - International Journal of Tuberculosis and Lung Disease